January 5, 2017
Neovacs and Professor Robert Kerbel together fight cancer
Neovacs and Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada are about to join…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
January 4, 2017
Bayer nets FDA’s priority review for cancer drug in U.S.
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
January 4, 2017
FDA said ok to Allergen’s breast implants
Allergan has won FDA’s approval to sell its breast implants in US.
December 30, 2016
Mylan launches three different tablets in US in two days
Mylan has had a rather busy week, as it got approvals for three of its generic medicines in last three days. It announced launching three generics into the multi-billion U.S. worth market on Wednesday and Thursday.
December 29, 2016
argenx publishes data from acute myeloid leukemia drug study
Argenx (argenx) is currently working on a therapy for the treatment of acute myeloid leukemia (AML), and during the holiday season, the company has revealed how it is going.
December 27, 2016
Seattle Genetics’ cancer drug put on clinical hold after four deaths
Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies.
December 27, 2016
Shire’s Adynovate cleared for young children haemaphilia patients
Shire will now be able to use its Adynovate for treating heamophilia A in children younger than 12 years of age, as the the U.S. Food and Drug Administration (FDA) has approved it for that age group. The FDA has also…
December 23, 2016
TiGenix submits Day 120 Responses to EMA for Crohn`s disease drug
TiGenix has submitted its responses to the European Medicines Agency`s (EMA) Day 120 List of Questions for Cx601, its lead…
December 23, 2016
Roche’s haemophilia drug reduces number of bleeds, study shows
Roche’s phase III study of haemophilia drug emicizumab prophylacis for 12 yearolds and older has met its primary endpoint, as…
December 22, 2016
ImmuPharma recruits patients for Phase III study of Lupuzor
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…